MapLight Therapeutics, Inc. Proceeds from Issuance of Convertible Preferred Stock
MapLight Therapeutics, Inc. (MPLT) reported Proceeds from Issuance of Convertible Preferred Stock of $198.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2026-03-26
- MapLight Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2025-12-31 was -$30.00K.
- MapLight Therapeutics, Inc. proceeds from issuance of convertible preferred stock for fiscal 2025 was $198.84M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|
| 2025-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $198.84M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $198.87M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |